Novo Nordisk A/S Sponsored ADR (0TDD)
LSE
Closed
Aug 24, 2026
Day's Range
46.5652 wk Range
35.09Profile - 0TDD - Novo Nordisk A/S Sponsored ADR
Profile
Mic Code
XLON
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
78.38K
Novo Nordisk is a leading global pharmaceutical company headquartered in Denmark that specializes in developing and manufacturing medicines to treat serious chronic diseases. The company focuses on four primary therapeutic areas: diabetes, obesity, cardiovascular disease, and rare diseases including hemophilia and growth disorders. Its product portfolio includes diabetes treatments like Tresiba and Rybelsus, obesity medications such as Wegovy, cardiovascular and rare disease therapies, and hormone replacement treatments. Novo Nordisk operates manufacturing facilities across multiple continents and maintains research and development centers worldwide, serving millions of patients globally. The company is backed by the Novo Nordisk Foundation, one of the world's largest philanthropies, which influences its approach to healthcare innovation and patient access. Founded on principles emphasizing scientific excellence and compassion, Novo Nordisk combines breakthrough pharmaceutical research with a commitment to expanding medicine accessibility and working toward disease prevention and cure.
Profile Details
Type
American Depositary Receipt
Address
Novo Alle 1
City
Bagsvaerd
Zip
2880
Country
Denmark
Phone
45 44 44 88 88
Key Executives - 0TDD - Novo Nordisk A/S Sponsored ADR
Key executives
Cross Listings - 0TDD - Novo Nordisk A/S Sponsored ADR
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
